MARKET

XBIO

XBIO

Xenetic Biosciences Inc
NASDAQ
3.770
-0.210
-5.28%
Closed 16:00 03/28 EDT
OPEN
3.897
PREV CLOSE
3.980
HIGH
3.900
LOW
3.770
VOLUME
3.95K
TURNOVER
0
52 WEEK HIGH
5.97
52 WEEK LOW
2.550
MARKET CAP
5.81M
P/E (TTM)
-1.3935
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at XBIO last week (0318-0322)?
Weekly Report · 4d ago
CORRECTION: On Friday, Xenetic Biosciences Q4 GAAP EPS $(0.77) Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $0.77 per share. The company reported quarterly sales of $671.96 thousand. Xenetic beat the analyst consensus estimate of $680.00 thousand by 11.49 percent.
Benzinga · 4d ago
Xenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial Future
TipRanks · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xenetic Biosciences (XBIO) and Dianthus Therapeutics (DNTH)
TipRanks · 03/22 12:31
Xenetic Biosciences reports FY results
Seeking Alpha · 03/22 12:14
Xenetic Biosciences Q4 EPS $0.77 Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly earnings of $0.77 per share. The company reported quarterly sales of $671.96 thousand. Xenetic beat the analyst consensus estimate of $680.00 thousand by 1.18 percent.
Benzinga · 03/22 12:03
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
Xenetic Biosciences reported earnings per share of 77 cents for the fourth quarter of 2023. The company reported revenue of $671,963. This was 1.18% worse than the analyst estimate for revenue. Xenetic B biosciences also reported results for the third quarter of 2018.
Investorplace · 03/22 11:53
Xenetic Dips on Full-Year Results
Xenetic Biosciences, Inc. Shares fell 30 cents, or 7.6%, to $3.65 on Friday. The company reported its financial results for the year ended December 31, 2023. XBIO is focused on advancing innovative immune-oncology technologies.
Barchart · 03/22 08:56
More
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.

Webull offers Xenetic Biosciences Inc stock information, including NASDAQ: XBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XBIO stock methods without spending real money on the virtual paper trading platform.